Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis

doi:10.3748/wjg.v27.i11.1064

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4629)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

327

WORD

216

HTML

2224

Figures (1-2)

279

Tables (1-5)

282

Sum=3328

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

364

Download

937

Sum=1301

Mar 21, 2021 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Mar 21, 2021; 27(11): 1064-1075
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1064

Table 1 Demographic and clinical profile of all candidate patients for liver transplant according to E2, E3 and E4 allele stratification

Variables	*APOE*2	*APOE*3	*APOE*4	P value
Age (yr) (mean ± SD)	60.8 ± 7.26	60.3 ± 7.19	60.3 ± 7.44	0.956
BMI (mean ± SD)	27.6 ± 4.36	26.4 ± 5.01	27.0 ± 4.81	0.167
Gender (n¹= 179; n²= 358), n²(%)
Male (n¹= 145; n²= 290)	52 (17.9)	193 (66.6)	45 (15.5)	0.650
Female (n¹= 34; n²= 68)	9 (13.2)	48 (70.6)	11 (16.2)	0.650
BMI (n¹= 179; n²= 358), n²(%)
Non-obese (n¹= 137; n²= 274)	49 (17.9)	185 (67.5)	40 (14.6)	0.519
Obese (n¹= 42; n²= 84)	12 (14.3)	56 (66.7)	16 (19.0)	0.519
Etiology (n¹= 179; n²= 358), n²(%)
HCV (n¹= 74; n²= 148)	24 (16.2)	96 (64.9)	28 (18.9)	0.357
HCV + HCC (n¹= 105; n²= 210)	37 (17.6)	145 (69.0)	28 (13.3)	0.357
HCC Milan (n¹= 105; n²= 210), n²(%)
Within the criteria (n¹= 83; n²= 166)	29 (17.5)	115 (69.3)	22 (13.2)	0.885
Outside the criteria (n¹= 22; n²= 44)	8 (18.2)	29 (65.9)	7 (15.9)	0.885

Of 105 patients complicated with hepatocellular carcinoma. n¹: Number of subjects; n²: Number of alleles; APOE: Apolipoprotein E gene; BMI: Body mass index; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.

Table 2 Genotypic and allele distribution of apolipoprotein E according to group, hepatitis C virus serology/viral load and severity of liver inflammation by the METAVIR score of the total population

*APOE* genotype		Group		HCV-RNA		METAVIR		METAVIR
	All	HCV	HCV + HCC	Positive	Negative	≤ A2F4	A3F4	A1F4	A3F4
	n¹ (179)	n¹(74)	n¹(105)	n¹(33)	n¹(146)	n¹(80)	n¹(11)	n¹(27)	n¹(11)
E2/E2	15 (8.4)	6 (8.1)	9 (8.6)	7 (21.2)	8 (5.5)	9 (11.2)	1 (9.1)	4 (14.8)	1 (9.1)
E2/E3	25 (14.0)	9 (12.2)	16 (15.2)	3 (9.1)	22 (15.1)	11 (13.8)	2 (18.2)	4 (14.8)	2 (18.2)
E2/E4	6 (3.3)	3 (4.1)	3 (2.9)	0 (0.0)	6 (4.1)	2 (2.5)	0 (0.0)	1 (3.7)	0 (0.0)
E3/E3	92 (51.4)	36 (48.6)	56 (53.3)	16 (48.5)	76 (52.0)	39 (48.8)	8 (72.7)	12 (44.5)	8 (72.7)
E3/E4	32 (17.9)	15 (20.3)	17 (16.2)	5 (15.1)	27 (18.5)	14 (17.5)	0 (0.0)	3 (11.1)	0 (0.0)
E4/E4	9 (5.0)	5 (6.7)	4 (3.8)	2 (6.1)	7 (4.8)	5 (6.2)	0 (0.0)	3 (11.1)	0 (0.0)
*APOE* alleles	n²(%)	n²(%)	n²(%)	n²(%)	n²(%)	n²(%)	n²(%)	n²(%)	n²(%)
E2	61 (17.1)	24 (16.2)	37 (17.6)	17 (25.8)	44 (15.1)	31 (19.4)	4 (18.2)	13 (24.1)	4 (18.2)
E3	241 (67.3)	96 (64.9)	145 (69.1)	40 (60.6)	201 (68.8)	103 (64.4)	18 (81.8)	31 (57.4)	18 (81.8)
E4	56 (15.6)	28 (18.9)	28 (13.3)	9 (13.6)	47 (16.1)	26 (16.2)	0(0.0)	10 (18.5)	0 (0.0)
All	358	148	210	66	292	160	22	54	22

METAVIR score of biopsies liver explants from 89 patients and from 2 patients in pre-transplant. n¹: Number of subjects; n²: Number of alleles; APOE: Apolipoprotein E gene; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.

Table 3 METAVIR scores for liver inflammation in pre-orthotopic liver transplantation patients according to E2, E3 and E4 alleles stratification

METAVIR score	*APOE*2			*APOE*3			*APOE*4
	Yes	No		Yes	No		Yes	No
	n²(%)	n²(%)	P value	n²(%)	n²(%)	*P value*	n²(%)	n²(%)	P value
METAVIR (n¹= 38; n²= 76)
A1F4 (n¹= 27; n²= 54)	13 (24.1)	41 (75.9)	0.764	31 (57.4)³	23 (42.6)	0.064	10 (18.5)	44 (81.5)	0.055
A3F4 (n¹= 11; n²= 22)	4 (18.2)	18 (81.8)	0.764	18 (81.8)	4 (18.2)	0.064	0 (0.0)¹	22 (100.0)	0.055
METAVIR (n¹= 91; n²= 182)
≤ A2F4 (n¹= 80; n²= 160)	31 (19.4)	129 (80.6)	1.000	103 (64.4)⁴	57 (35.6)	0.148	26 (16.2)	134 (83.8)	0.048^a
A3F4 (n¹= 11; n²= 22)	4 (18.2)	18 (81.8)	1.000	18 (81.8)	4 (18.2)	0.148	0 (0.0)²	22 (100.0)	0.048^a

n¹: Number of subjects; n²: Number of alleles.

³APOE3 vs APOE4 allele frequency, P = 0.024.

⁴APOE3 vs APOE4 allele frequency, P = 0.043.

^aP < 0.05. METAVIR A1: Minimal degree of inflammation; METAVIR A1A2: Minimal and moderate degree of inflammation; METAVIR A3: High degree of inflammation; APOE: Apolipoprotein E gene.

Table 4 Association of the models for end-stage liver disease score and variables in pre-orthotopic liver transplantation patients according to E2, E3 and E4 allele stratification

Variables	MELD≤ 25				MELD> 25				MELD≤ 25			MELD> 25
	*APOE*2	*APOE*3	*APOE*4		*APOE*2	*APOE*3	*APOE*4		*APOE4*			*APOE*4
	*APOE*2	*APOE*3	*APOE*4		*APOE*2	*APOE*3	*APOE*4		(Yes)	(No)		(Yes)	(No)
	n²(%)	n²(%)	n²(%)	P value	n²(%)	n²(%)	n²(%)	P value	n²(%)	n²(%)	P value	n²(%)	n²(%)	P value
METAVIR (n¹= 38; n²= 76)
A1F4 (n¹= 27; n²= 54)	9 (20.4)	27 (61.4)³	8 (18.2)	0.085	4 (40.0)	4 (40.0)	2 (20.0)	NA	8 (18.2)	36 (81.8)	0.044^a	2 (20.0)	4 (80.0)	NA
A3F4 (n¹= 11; n²= 22)	4 (18.2)	18 (81.8)	0 (0.0)³	0.085	0 (0.0)	0 (0.0)	0 (0.0)	NA	0 (0.0)	22 (100.0)	0.044^a	0 (0.0)	0 (0.0)	NA
METAVIR (n¹= 91; n²= 182)
≤ A2F4 (n¹= 80; n²= 160)	26 (18.6)	92 (65.7)⁴	22 (15.7)	0.123	5 (25.0)	11 (55.0)	4 (20.0)	NA	22 (15.7)	118 (84.3)	0.046^a	4 (20.0)	16 (80.0)	NA
A3F4 (n¹= 11; n²= 22)	4 (18.2)	18 (81.8)	0 (0.0)⁴	0.123	0 (0.0)	0 (0.0)	0 (0.0)	NA	0 (0.0)	22 (100.0)	0.046^a	0 (0.0)	0 (0.0)	NA

n¹: Number of subjects; n²: Number of alleles.

³APOE3 vs APOE4 allele frequency, P = 0.040.

⁴APOE3 vs APOE4 allele frequency, P = 0.042.

^aP < 0.05. METAVIR F4: Cirrhosis; METAVIR A1: Minimal degree of inflammation; METAVIR A1A2: Minimal and moderate degree of inflammation; METAVIR A3: High degree of inflammation; APOE: Apolipoprotein E gene; MELD: Model for end-stage liver disease; NA: Not applicable.

Table 5 Logistic regression model predicting moderate and severe (A2A3) degree of liver inflammation

Variables	Odds ratio	95%CI	P value
Alcohol consumption	0.636	0.188-2.148	0.466
Gender–male	7.609	1.195-48.447	0.032^a
Mean MELD	0.932	0.829-1.049	0.244
Mean age	0.969	0.893-1.051	0.446
Mean BMI	0.874	0.782-0.976	0.017^a
APOE2	1.519	0.059-39.334	0.801
APOE3	2.850	0.121-66.917	0.516
APOE4	2.868	0.112-73.560	0.524

^aP < 0.05. MELD: Model for end-stage liver disease; BMI: Body mass index; APOE: Apolipoprotein E gene; CI: Confidence interval.

Citation: Nascimento JCR, Pereira LC, Rêgo JMC, Dias RP, Silva PGB, Sobrinho SAC, Coelho GR, Brasil IRC, Oliveira-Filho EF, Owen JS, Toniutto P, Oriá RB. Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis. World J Gastroenterol 2021; 27(11): 1064-1075
URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1064.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1064